<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>337</serviceExecutionTime><Drug id="83503"><DrugName>ENN-11</DrugName><DrugSynonyms><Name><Value>ENN-11</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1074766">Ennar Pharma AG</CompanyOriginator><CompaniesSecondary><Company id="1074766">Ennar Pharma AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1074766" type="Company"><TargetEntity id="5037940819" type="organizationId">Ennar Pharma AG in Liquidation</TargetEntity></SourceEntity><SourceEntity id="723" type="ciIndication"><TargetEntity id="10040943" type="MEDDRA"></TargetEntity><TargetEntity id="D012883" type="MeSH"></TargetEntity><TargetEntity id="-1807650329" type="omicsDisease"></TargetEntity><TargetEntity id="497" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="723">Skin ulcer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1880">Dermatological agent</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-24T08:40:56.000Z</LastModificationDate><ChangeDateLast>2014-07-10T00:00:00.000Z</ChangeDateLast><AddedDate>2013-02-25T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1074766" linkType="Company"&gt;Ennar Pharma&lt;/ulink&gt; was investigating ENN-11 for the potential treatment of skin ulcers. In February 2013, the drug was listed as being in preclinical development [&lt;ulink linkID="1385899" linkType="Reference"&gt;1385899&lt;/ulink&gt;]; however, in January 2014,  the company has  discontinued development of all the programs [&lt;ulink linkID="1576217" linkType="Reference"&gt;1576217&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1074766">Ennar Pharma AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="723">Skin ulcer</Indication><StatusDate>2014-07-10T00:00:00.000Z</StatusDate><Source id="1576217" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1074766">Ennar Pharma AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="723">Skin ulcer</Indication><StatusDate>2013-02-25T00:00:00.000Z</StatusDate><Source id="1385899" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>